Objective This study aimed to to perform genotyping of Toxoplasma gondii strain or variant causing atypical toxoplasmic uveitis in Indonesia patients. Methods Ocular fluid samples originated from 46 uveitis patients with non-specific ocular manifestation were analyzed forToxoplasma infection by PCR of the B1 locus. The clonal type was determined by amplification, sequencing and phylogenetic analysis of SAG2 and GRA6 loci in B1-positive samples. Clinical data was obtained from the medical records. https://www.selleckchem.com/products/oligomycin-a.html Results Pan uveitis was the most frequent manifestation (65.2%) and mostly unilateral (76.1%). PCR of the B1 locus identified 8 positive subjects (12.5%), majorly with panuveitis (n = 6); two of these individuals had diabetes mellitus. Phylogenetic analysis with maximum likelihood, of the SAG2 locus in the B1-positive samples resulted T. gondii SAG2 type III allele. No positive result was obtained from PCR of GRA6 locus. Conclusion Toxoplasma gondii SAG2-type III allele was identified in atypical presentation of toxoplasmic uveitis in Indonesia.Mitotic progression is orchestrated by the microtubule-based motor dynein, which sustains all mitotic spindle functions. During cell division, cytoplasmic dynein acts with the high-molecular-weight complex dynactin and nuclear mitotic apparatus (NuMA) to organize and position the spindle. Here, we analyze the interaction interface between NuMA and the light intermediate chain (LIC) of eukaryotic dynein. Structural studies show that NuMA contains a hook domain contacting directly LIC1 and LIC2 chains through a conserved hydrophobic patch shared among other Hook adaptors. In addition, we identify a LIC-binding motif within the coiled-coil region of NuMA that is homologous to CC1-boxes. Analysis of mitotic cells revealed that both LIC-binding sites of NuMA are essential for correct spindle placement and cell division. Collectively, our evidence depicts NuMA as the dynein-activating adaptor acting in the mitotic processes of spindle organization and positioning.Pitaya (Hylocereus spp.) is the only commercial cultivation of fruit containing abundant betalains for consumer. Betalains are water-soluble nitrogen-containing pigments with high nutritional value and bioactivities. In this study, contents of betaxanthins and betacyanins were compared between 'Guanhuabai' (H. undatus) and 'Huanglong' (H. megalanthus) pitayas and key genes involved in betalain biosynthesis were screened from 'Huanglong' pitaya by RNA-Seq technology. Twenty-nine candidate genes related to betalain biosynthesis were obtained from the transcriptome data. Based on expression characteristics and sequence analyses, HmB5GT1 and HmHCGT2 were further analyzed. HmB5GT1 and HmHCGT2 were both conserved in 'PSPG-box' and localized in nucleus. Silencing of HmB5GT1 and HmHCGT2 resulted in a significant reduction in betacyanin and betaxanthin contents. Those results suggested that HmB5GT1 and HmHCGT2 are possibly involved in betalain biosynthesis in H. megalanthus. The present work provides new information on betalain biosynthesis in Hylocereus at the transcriptional level.The aim of this study was to substitute part of soybean phospholipid (SPC) with hydrogenated soybean phospholipid (HSPC) in curcumin-loaded liposomes (Cur-LP), in order to further enhance stability and release performances of curcumin. When the SPC/HSPC mass ratio changed from 100 to 55, vesicle size, encapsulation efficiency and alkali resistance of curcumin increased, although a small decrease in centrifugal stability was observed. Salt stability became worse as more HSPC was used (37 and 010). Owing storage at 4 °C and 25 °C, Cur-LP at a SPC/HSPC mass ratio of 55 performed well considering vesicle size, lipid oxidation and curcumin retention. These vesicles displayed also the best sustained-release performance in simulated digestion, attributed to the tighter lipid packing in membranes as indicated by fluorescence probes, DSC and FTIR. This study can guide the development of a Cur-LP product with improved shelf-life stability by using HSPC.Since its introduction to clinical practice, preimplantation genetic testing (PGT) has become a standard of care for couples at risk of having children with monogenic disease, and for chromosomal aneuploidy to improve outcomes for patients with infertility. The primary objective of PGT is to reduce the risk of miscarriage and genetic disease and to improve the success of infertility treatment with the delivery of a healthy child. Until recently, the application of PGT to more common but complex polygenic disease was not possible, as the genetic contribution to polygenic disease has been difficult to determine, and the concept of embryo selection across multiple genetic loci has been difficult to comprehend. Several achievements, including the ability to obtain accurate, genome-wide genotypes of the human embryo, and the development of population level biobanks have now made PGT for polygenic disease risk applicable in clinical practice. With the rapid advances in embryonic polygenic risk scoring, diverse considerations beyond technical capability have been introduced.Experimental information from microscopy, structural biology, and bioinformatics may be integrated to build structural models of entire cells with molecular detail. This integrative modeling is challenging in several ways the intrinsic complexity of biology results in models with many closely packed and heterogeneous components; the wealth of available experimental data is scattered among multiple resources and must be gathered, reconciled, and curated; and computational infrastructure is only now gaining the capability of modeling and visualizing systems of this complexity. We present recent efforts to address these challenges, both with artistic approaches to depicting the cellular mesoscale, and development and application of methods to build quantitative models.Pulmonary arterial hypertension remains a progressive, life-limiting disease despite optimal medical therapy. Pulmonary artery denervation has arisen as a novel intervention in the treatment of pulmonary arterial hypertension, and other forms of pulmonary hypertension, with the aim of reducing the sympathetic activity of the pulmonary circulation. Pre-clinical studies and initial clinical trials have demonstrated that the technique can be performed safely with some positive effects on clinical, haemodynamic and echocardiographic markers of disease. The scope of the technique in current practice remains limited given the absence of well-designed, large-scale, international randomised controlled clinical trials. This review provides an overview of this exciting new treatment modality, including pathophysiology, technical innovations and recent trial results.